Salmeterol Fluticasone

ApprovedSmall molecule

Salmeterol Fluticasone is one of 77 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Adverse EffectActive, not recruiting

AsthmaActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 3

Active, not recruiting

Adverse EffectApproved

Active, not recruiting

AsthmaApproved

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Salmeterol Fluticasone

AstraZeneca

Approved

1 2

Veramyst

GSK

Preclinical

46 3

Xolair

Roche

Preclinical

25 4

Cinqair

Teva

Preclinical

13 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Spiriva

Boehringer Ingelheim

Preclinical

8 7

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 8

Arcoxia

Novartis

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Salmeterol2 trials

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

Completed· Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma·Phase 1·NCT03238482·64 enrolled

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

Withdrawn·NNorthwestern University·N/A·NCT00741767

Asthma1 trial

Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma

Completed·UUniversità degli Studi di Brescia·Phase 4·NCT01255579·10 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01908140·933 enrolled

Adverse Effect1 trial

Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma

Unknown status·IImperial College London·Phase 4·NCT04503460·24 enrolled

Trial1 trial

Replication of the INSPIRE Trial in Healthcare Claims Data

Completed·—··NCT05179512·98,278 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Salmeterol Fluticasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Salmeterol Fluticasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Salmeterol Fluticasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Salmeterol Fluticasone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Salmeterol2 trials

Asthma1 trial

Chronic Obstructive Pulmonary Disease1 trial

Adverse Effect1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News